Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,644,648
  • Shares Outstanding, K 1,478,821
  • Annual Sales, $ 32,753 M
  • Annual Income, $ 5,687 M
  • 60-Month Beta 0.98
  • Price/Sales 4.01
  • Price/Cash Flow 9.50
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 2.24
  • Number of Estimates 2
  • High Estimate 2.27
  • Low Estimate 2.20
  • Prior Year 1.90
  • Growth Rate Est. (year over year) +17.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.85 +15.58%
on 10/21/19
90.41 -3.03%
on 11/19/19
+11.21 (+14.66%)
since 10/18/19
3-Month
64.44 +36.05%
on 09/04/19
90.41 -3.03%
on 11/19/19
+21.26 (+32.01%)
since 08/20/19
52-Week
62.66 +39.91%
on 08/15/19
94.98 -7.70%
on 12/04/18
-0.42 (-0.48%)
since 11/20/18

Most Recent Stories

More News
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - November 20, 2019

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate...

ABBV : 87.65 (-1.54%)
CMRE : 8.13 (-3.21%)
CAKE : 42.61 (-0.07%)
Patients Seek Non-Opioid Options for Cancer Pain Management

In 2019, the American Cancer Society is estimating a total of 1.76 million new cancer cases and 606,880 cancer-related deaths in the U.S. The National Cancer Institute expects prostate, lung, breast, and...

QBIO : 1.4100 (+286.30%)
BAYRY : 19.1100 (-1.60%)
NVS : 90.59 (+0.21%)
LLY : 114.37 (-0.63%)
ABBV : 87.65 (-1.54%)
Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

Dragonfly will use its TriNKET(TM) platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology. AbbVie receives exclusive options to license a number of Dragonfly's...

ABBV : 87.65 (-1.54%)
5 Corporate Giants That Popped After Latest Earnings Release

A few corporate behemoths that reported their last earnings results less than five weeks ago, popped after releasing earnings results.

ABBV : 87.65 (-1.54%)
AAPL : 264.27 (-0.76%)
MSFT : 150.12 (-0.18%)
UNH : 274.51 (+0.10%)
INTC : 58.21 (-0.24%)
Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.

ABBV : 87.65 (-1.54%)
RHHBY : 38.2100 (-0.23%)
PFE : 37.19 (-1.25%)
AMGN : 224.40 (-0.04%)
Abbvie Inc Up 26.0% Since SmarTrend Uptrend Call (ABBV)

SmarTrend identified an Uptrend for Abbvie Inc (NYSE:ABBV) on September 12th, 2019 at $70.68. In approximately 2 months, Abbvie Inc has returned 25.98% as of today's recent price of $89.04.

ABBV : 87.65 (-1.54%)
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding...

AGN : 184.69 (-0.29%)
ABBV : 87.65 (-1.54%)
Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

ABBV : 87.65 (-1.54%)
PFE : 37.19 (-1.25%)
AZN : 47.16 (-1.07%)
GSK : 43.92 (-1.30%)
MRK : 84.73 (+0.09%)
BMY : 55.89 (-1.04%)
LLY : 114.37 (-0.63%)
4 Big Drugmakers to Bet on After a Great Earnings Season

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

ABBV : 87.65 (-1.54%)
PFE : 37.19 (-1.25%)
NVO : 54.39 (-4.65%)
BMY : 55.89 (-1.04%)
MRK : 84.73 (+0.09%)
GSK : 43.92 (-1.30%)
JNJ : 135.37 (+0.41%)
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue

In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 11, 2019 its issued share capital, excluding treasury shares, is comprised...

ABBV : 87.65 (-1.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ABBV with:

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 90.95
1st Resistance Point 89.98
Last Price 87.66
1st Support Level 88.48
2nd Support Level 87.95

See More

52-Week High 94.98
Last Price 87.66
Fibonacci 61.8% 82.63
Fibonacci 50% 78.82
Fibonacci 38.2% 75.01
52-Week Low 62.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar